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Patients randomized to placebo in the encainide and flecainide 
arms of the Cardiac Arrhythmia Suppression Trial (CAST) have 
been found to have a relatively low 1-year mortality rate of 3.9% 
in comparison with previous studies of patients in the postmyo-
cardial infarction period. To determine the comparability of 
CAST with previous studies, baseline variables were examined in 
the 743 patients randomized to placebo in the flecainide and 
encainide arms of CAST. Twenty-three baseline characteristics 
were correlated with major outcome events: arrhythmic death 
(16 events), total mortality (26 events) and congestive heart failure 
(51 events). 
On multivariate analysis the risk of new or worsening conges-
tive heart failure was significantly associated with diuretic use, 
diabetes, high New York Heart Association functional class, age, 
prolonged QRS duration and low ejection fraction. The risk of 
arrhythmic death or resuscitated cardiac arrest was significantly 
The Cardiac Arrhythmia Suppression Trial (CAST) is a 
large, prospective, double-blind, placebo-controlled study 
undertaken to test the hypothesis that pharmacologic sup-
pression of asymptomatic or mildly symptomatic ventricular 
premature depolarizations will result in a reduction of the 
risk of arrhythmic death after myocardial infarction. Unlike 
other trials of antiarrhythmic therapy in the postmyocardial 
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associated with an index Q wave myocardial infarction, history of 
heart failure, use of digitalis, diabetes and prolonged QRS dura-
tion. Total mortality or resuscitated cardiac arrest was signifi-
cantly associated with an index Q wave. myocardial infarction, 
diabetes, ST segment depression, high functional class, prolonged 
QRS duration and low ejection fraction. 
The variables at baseline associated with mortality from all 
causes or arrhythmic death or resuscitated cardiac arrest and 
heart failure in the CAST placebo-treated patients are similar to 
those identified in previous postmyocardial infarction studies. 
Thus, the observation of increased mortality in CAST associated 
with the administration of encainide and flecainide for suppression 
of ventricular premature depolarizations is probably applicable to 
any comparably defined group of patients in the postmyocardial 
infarction period. 
(JAm Coil Cardio/1991;18:1434-8) 
infarction period, CAST was designed to mimic clinical 
practice by including an open label titration phase, during 
which a patient was randomly assigned to one of four 
possible titration sequences, utilizing a maximum of three 
drugs at two doses each to identify one that was associated 
with :::::80% suppression of ventricular premature depolariza-
tions and :::::90% suppression of nonsustained ventricular 
tachycardia. If such a drug and dose combination was found, 
the patient was randomized to treatment with the active 
agent or a matching placebo. This element of the CAST 
design seems to have had a significant effect on the study 
patients in that the estimated 1-year mortality rate of 3.9% 
for the placebo group of the encainide and fiecainide arms of 
the trial appears to be relatively low compared with that of 
previous studies of patients recovering from myocardial 
infarction. 
In this study, we investigated the association between the 
baseline variables and arrhythmic death, total mortality and 
congestive heart failure to determine the comparability of 
the CAST placebo group with those described in previous 
postmyocardial infarction studies. Because these patients 
are not treated with antiarrhythmic agents, this investigation 
also provides an important natural history study of patients 
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in the myocardial infarction period who have suppressible 
ventricular premature depolarizations. 
Methods 
Study design. A detailed summary of CAST study design 
has been previously published (1). In brief, all patients had 
had an acute myocardial infarction within the previous 2 
years and had an average of six or more ventricular prema-
ture depolarizations per hour on 24-h ambulatory electrocar-
diography (ECG) recording. A left ventricular ejection frac-
tion of :50.55 was required for those whose myocardial 
infarction had occurred within 90 days; those whose infarc-
tion had occurred >90 days but <2 years before the study 
were required to have an ejection fraction of :50.40. As 
previously described in detail (2), subjects were tested in 
open label titration with encainide, flecainide or moricizine 
for the required suppression of ventricular premature depo-
larizations and ventricular tachycardia. Because of its rec-
ognized mild myocardial depressant effects, flecainide was 
not included in the titration scheme for those subjects with 
an ejection fraction :50.30. Subjects who had ~80% suppres-
sion of ventricular premature depolarizations and ~90% 
suppression of ventricular tachycardia were then random-
ized in double-blind fashion to the effective agent or its 
placebo. 
Patient baseline variables. For this analysis, we examined 
selected baseline variables in the 743 patients randomized in 
CAST to encainide placebo (n = 425) or flecainide placebo 
(n = 318). The baseline variables used in this analysis were 
selected by the investigators on the basis of previously 
published studies, and the list was modified to include 
variables that were also thought to influence the end points. 
In all, 23 variables were studied: age; male gender; history of 
previous myocardial infarction or congestive heart failure; 
cigarette smoking within the month preceding myocardial 
infarction; use of diuretic drugs, digitalis or a beta-
adrenergic blocking agent; presence of diabetes or hyperten-
sion; administration of thrombolytic therapy during the 
index acute myocardial infarction; left ventricular ejection 
fraction; New York Heart Association functional class; 
Canadian Cardiovascular Society class for angina; number 
of days from the index myocardial infarction to the beginning 
of CAST open label drug titration; number of ventricular 
premature depolarizations or runs of ventricular tachycardia 
(~3 to < 15 ventricular premature depolarizations in series at 
a rate ~ 120/min) on the baseline Holter ambulatory electro-
cardiogram (ECG) monitor; presence of Q wave myocardial 
infarction, QRS duration, ST segment depression or eleva-
tion ~ 1 mm or QT interval prolongation ~0.39 s on the 
enrollment ECG; and untreated serum cholesterol >210 mg/dl. 
There were no patients in functional class IV and a limited 
number in class III; extrapolation of the results beyond class II 
must therefore be made with caution. Exercise testing was not 
a requirement for entry into the study and is not included 
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among the baseline variables evaluated. The average follow-up 
duration was 10 months. 
End points for analysis. These included: 1) arrhythmic 
death or resuscitated cardiac arrest, the main CAST end 
point; 2) total mortality or resuscitated cardiac arrest, a 
secondary CAST end point; and 3) new or worsening con-
gestive heart failure. Arrhythmic death was defined as in-
stantaneous death in the absence of severe congestive heart 
failure or shock, unwitnessed death without a preceding 
change in symptoms for which no other cause could be 
ascribed or documented cardiac arrest. Each death and 
resuscitated cardiac arrest was reviewed by the Events 
Committee, which is composed of CAST investigators who 
did not know the treatment assignment of each subject 
evaluated. New congestive heart failure was defined as the 
appearance of at least two of the following symptoms or 
signs when none was noted at baseline study: shortness of 
breath, easy fatigability, edema, orthopnea, paroxysmal 
nocturnal dyspnea, jugular venous distension, rales and a 
third heart sound (S3). Worsening congestive heart failure 
was defined as an increase in one or more functional class. 
The study protocol was approved by the Institutional 
Review Board of each participating clinical center and by an 
independently appointed external study Data and Safety 
Monitoring Board. Written informed consent was obtained 
from all patients participating in the study. 
Statistical methods. We analyzed two-way contingency 
tables for the univariate analysis using the standard chi-
square test. All p values are two-sided and declared signifi-
cant if :50.05. Multivariate analyses of all end points were 
done with use of the Cox proportional hazard regression 
model. The exposure time began at the time of randomiza-
tion to blinded therapy; patients who were still alive on April 
18, 1989, the date on which the study Data and Safety 
Monitoring Board recommended that the encainide and 
flecainide arms of CAST be terminated, had exposure time 
censored at that point. The exposure time for congestive 
heart failure was censored at the time of death or cardiac 
arrest or on April 18, 1989, and only the event was consid-
ered in the analysis. In the multivariate analysis, the varia-
bles were entered into the model by a stepwise procedure 
until none of the remaining variables outside of the model 
was significant. 
Results 
A total of 743 patients were assigned to placebo therapy 
on encainide or flecainide between June 15, 1987 and April 
17, 1989. The average follow-up was about 10 months. 
Results of the univariate analyses of the 23 baseline factors 
are shown on Table 1. Results of the multivariate analysis 
are summarized in Table 2. 
New or worsening congestive heart failure. There were 51 
subjects who experienced new or worsening congestive 
heart failure. On univariate analysis, 11 variables were 
significantly associated with this outcome, with 1 (namely, 
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Table 1. Univariate Analysis of Significant Baseline Factors During Follow-Up in 743 Encainide 
and Flecainide Placebo-Treated Subjects in the Cardiac Arrhythmia Suppression Trial 
Baseline Variable 
Age >65 years 
No. of men 
History of CHF 
History of MI 
Diuretic use 
Diabetes 
Digitalis use 
Hypertension 
Thrombolysis 
EF <0.30 
NYHA functional class 
Class I vs. no CHF 
Class 2 vs. class I 
24-h amb ECG 
No. of VT runs 
Baseline ECG 
Q wave MI 
QRS ~100 ms 
ST ~ ~I mm 
Congestive Heart 
Failure 
(n = 51) 
p Value Rei Risk 
0.002 2.4 
0.010 0.4 
<0.001 4.2 
0.063 1.7 
<0.001 5.0 
0.006 2.3 
0.171 1.6 
0.003 2.3 
0.009 0.3 
<0.001 3.8 
<0.001 
2.1 
2.5 
0.004 2.4 
0.896 1.0 
0.008 2.2 
0.080 1.7 
Outcome Variable 
Arrhythmic Death or 
Cardiac Arrest 
(n = 16) 
p Value Rei Risk 
0.032 2.9 
0.110 0.4 
<0.001 6.6 
0.104 2.2 
0.006 3.8 
0.186 3.1 
0.001 4.7 
0.322 1.6 
0.019 0.0 
0.001 4.6 
0.099 
0.702 1.3 
0.061 5.6 
0.139 2.1 
0.066 2.5 
All Cause Mortality 
(n = 26) 
p Value Rei Risk 
0.068 2.1 
0.148 0.5 
0.001 3.7 
0.068 2.1 
<0.001 3.7 
<0.001 4.2 
0.029 2.5 
0.124 1.8 
0.003 0.0 
0.005 3.2 
0.003 
2.5 
1.9 
0.804 1.1 
O.Q25 4.5 
0.040 2.3 
0.012 2.7 
*No events occurred for those in functional class I and relative risk is not calculated. Amb =ambulatory; CHF = 
congestive heart failure; ECG = electrocardiogram; EF = ejection fraction; MI = myocardial infarction; NYHA = 
New York Heart Association; Rei = relative; ST ~ = ST segment depression; VT = ventricular tachycardia. 
history of previous myocardial infarction) showing a trend 
toward significance. On multivariate analysis, diuretic use 
(hazard ratio 2.2), diabetes (hazard ratio 1.7), high functional 
class (hazard ratio 1. 7 /class), age (hazard ratio 1.4/standard 
deviation [SD] of 9.8 years), prolonged QRS complex dura-
tion (hazard ratio 1.4/SD of 19 ms) and low left ventricular 
ejection fraction (hazard ratio 1.7/SD of 0.09) were associ-
ated with new or worsened congestive heart failure during 
follow-up. 
Arrhythmic death or resuscitated cardiac arrest. Sixteen 
subjects experienced arrhythmic death or were resuscitated 
from cardiac arrest, an occurrence rate that would tend to 
limit the statistical power of the comparisons. On univariate 
analysis, six baseline variables were significantly associated 
with this end point, with one (namely, Q wave myocardial 
infarction) showing a trend toward significance. On multi-
variate analysis, Q wave myocardial infarction (hazard ratio 
7.5), history of congestive heart failure (hazard ratio 3.8), 
use of digitalis (hazard ratio 3.1), diabetes (hazard ratio 2.6) 
and prolonged QRS complex duration (hazard ratio 1.5/SD 
of 19 ms) were associated with sudden arrhythmic death or 
resuscitated cardiac arrest. 
Mortality from all causes or resuscitated cardiac arrest. 
There were 26 deaths in this group, of which 21 were 
cardiac. On univariate analysis, 10 baseline variables were 
significantly associated with this end point. On multivariate 
analysis, Q wave myocardial infarction (hazard ratio 7), 
diabetes (hazard ratio 4.7), ST segment depression (hazard 
ratio 2.4), high functional class (hazard ratio 1.5/class), 
prolonged QRS complex duration (hazard ratio 1.4/SD of 
19 ms) and low ejection fraction (hazard ratio 1.4/SD of0.09) 
were associated with total mortality. 
Discussion 
Mortality in the various CAST study groups. We (1) 
previously demonstrated that the mortality rate for patients 
with qualifying ventricular ectopic rhythm enrolled into 
CAST is comparable with that of other groups studied after 
acute myocardial infarction. This rate is in contrast to the 
mortality rate for patients in CAST randomized to placebo 
after demonstrating suppression of their ventricular arrhyth-
mia during open label titration. The difference in mortality 
rate, comparing those with qualifying witnessed ectopic 
rhythm with those randomized to placebo, may relate to the 
modifications in the composition of the originally qualified 
group of patients during the open label drug titration period 
(Fig. 1). Initially, all qualified patients in CAST were sub-
jected to a sequential scheme of antiarrhythmic treatment 
(2). Only those with ventricular ectopic rhythm that was 
suppressed by one of the agents included in CAST were 
randomized. During this open label titration period, death 
occurred in 63 (2.7%) of patients eligible for study (1 patient 
was successfully resuscitated from cardiac arrest and subse-
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Table 2. Multivariate Analysis of Baseline Risk Factors During Follow-Up in 743 Encainide and 
Flecainide Placebo-Treated Subjects in the Cardiac Arrhythmia Suppression Trial 
Baseline Variable 
Age/SDt 
History of CHF 
Diuretic use 
Digitalis use 
Diabetes 
Low EF/SD§ 
NYHA class/class 
Baseline ECG 
Q wave Ml 
QRS duration/SO~ 
ST! 2:1 mm 
New or Worsening 
Congestive Heart Failure 
Hazard Ratio 
1.4* 
2.2* 
1.7:j: 
1.7* 
1.611 
1.4* 
Arrhythmic Death 
or Cardiac Arrest 
Hazard Ratio 
3.8* 
7.5:j: 
1.5* 
All Cause 
Mortality 
Hazard Ratio 
4.711 
1.4:j: 
1.5* 
7* 
1.4* 
2.4* 
*p < 0.05. tStandard deviation (SD) = 9.8. :j:p < 0.1. §SD = 0.09.IIP < 0.01. ~SD = 19 ms. Abbreviations as in 
Table I. 
quently randomized). Deaths were related to factors at 
baseline study associated with increased risk: previous myo-
cardial infarction, more extensive left ventricular dysfunc-
tion and a prolonged interval from the index myocardial 
infarction. 
In addition to 78 patients who were in the open label 
titration phase on April 18, 1990 at the termination of the 
encainide and flecainide arms of the study, there were 318 
patients not randomized (because of adverse effects, lack of 
ventricular premature depolarization suppressibility or with-
drawal). This group had a mortality rate of8.5% as described 
in another report from this series (3). Thus, there were 1,913 
patients with suppressible ventricular ectopic rhythm who 
were eligible for randomization. Of these, 277 were assigned 
to participate in the moricizine arm (which was terminated in 
August 1991); 138 subjects demonstrated >0% but <80% 
suppression of ventricular premature depolarizations and 
were assigned to the substudy of patients with partial sup-
pression. Of the remaining 1,498 subjects, 755 were random-
ized to active encainide or fl.ecainide treatment; 743 were 
randomized to placebo and constitute the focus of this 
report. Thus, the net effect of the CAST design was to 
remove many patients at a potentially higher level of risk for 
death before randomization. 
Baseline variables as predictors of major events in the 
placebo groups. In the encainide and flecainide groups of 
patients randomized to placebo, we correlated 23 baseline 
variables with the major outcome events. Because there 
were very few noncardiac deaths in these patients, we chose 
variables that were largely cardiovascular in nature. Despite 
the elimination of many high risk patients before randomiza-
tion and the seemingly low 1-year mortality rate of 3.9% in 
placebo-treated patients, the variables identified as indepen-
dent predictors of sudden arrhythmic death, total mortality 
or development of congestive heart failure are remarkably 
similar to those found in other large postmyocardial infarc-
tion studies. 
For example, Goldstein et al. (4) noted that cardiomegaly, 
digitalis use, previous myocardial infarction, history of an-
gina and presence of ventricular premature depolarizations 
were independently associated with sudden cardiac death. In 
the Multicenter Investigation of the Limitation of Infarct 
Size (MILlS) (5), ejection fraction :s0.40, digitalis use and 
the presence of ventricular premature depolarizations were 
independent predictors of sudden death. Similarly, the Mul-
ticenter Postinfarction Research Group (6) found ejection 
fraction, high levels of ventricular premature depolariza-
tions and clinical signs of left ventricular dysfunction and 
digitalis treatment associated with total mortality. These 
same factors have been suggested (7-9) as predictors of 
total mortality in other postinfarction intervention trials. 
Diabetes also has been associated with an increase in car-
diovascular mortality (5,10,11), as have Q wave myocardial 
infarction (4) and persistent ST segment depression in pa-
tients with non-Q wave myocardial infarction (11). The 
factors found to be associated with congestive heart failure 
during the follow-up period are those traditionally associated 
with poor ventricular function and the development of heart 
failure (12-19) and primarily include increasing functional 
class, greater age, use of diuretic drugs and low ejection 
fraction. 
Role of frequency of ventricular premature depolariza-
tions. Conspicuously missing from significance in both 
univariate and multivariate analyses for death or cardiac 
arrest in this group of CAST placebo-treated patients is 
evidence of increased ventricular premature depolarization 
frequency, despite a high level of ventricular ectopic activity 
in the CAST encainide/fl.ecainide placebo group (mean 
frequency of ventricular premature depolarizations 130/h). 
The failure of our analysis to identify indexes incorporating 
some measure of ventricular ectopic rhythm may be related 
to the sigmoid relation between risk and ventricular prema-
ture beat activity in patients recovering from myocardial 
infarction as described by Bigger et al. (20) and to the 
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Total enrolled 
:ruratiQn 
Death or resuscitated 
cardiac arrest 
Titration not completed 
at termination of 
encainide/flecainide arms 
Not randomized 
Randomization 
Total randomized 
To moricizine 
(main study) 
To partially suppressed 
substudy 
To encainide/flecainide 
12371 1 
62 
78 
318 
277 
114981 
~ 
~ 17431 
Active 
Drug 
Placebo 
Figure 1. Disposition of the CAST-enrolled patients. 
exclusion in CAST of patients with few or no ventricular 
premature depolarizations. Thus, in the presence of a high 
level of ventricular ectopic activity, the level of risk remains 
relatively flat and little variation in risk can be anticipated 
with increases in ventricular premature depolarization fre-
quency. A low statistical power due to the small number of 
events may have also been responsible for this lack of 
correlation. It is also possible, however, that ventricular 
ectopic activity is not a risk factor in this group of patients 
with suppressible but untreated ventricular premature depo-
larizations. 
Conclusions. We examined 23 baseline characteristics of 
patients randomized to placebo in the encainide and 
ftecainide arms of CAST. We identified those characteristics 
associated with congestive heart failure, arrhythmic death or 
resuscitated cardiac arrest and total (all cause) mortality or 
resuscitated cardiac arrest outcomes and found them to be 
similar to baseline predictors identified in other postmyocar-
dial infarction studies. Thus, despite the relatively low 
mortality rate found in this group, we anticipate that the 
increased mortality rate found in CAST patients treated with 
encainide and ftecainide is probably applicable to any com-
parably defined group of patients in the postmyocardial 
infarction period. 
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